The MEA digital therapeutics market size surpassed USD 480 million in 2025 and is predicted to reach around USD 7421.62 million by 2035, registering a CAGR of 31.5% from 2026 to 2035. Due to rising chronic diseases and the strong government support for digital health care, especially in countries like Saudi Arabia and the UAE, Increased focus on remote and personalised care is improving treatment access and efficiency.

MEA Digital Therapeutics Market Statical Scope

It include the adoption of mobile apps, telemedicine , and digital tools for managing chronic and mental health conditions, these solutions help improve patient engagement and treatment adherence.

Growth is driven by high smartphone use, healthcare modernization and demand for cost- effective therapies, technologies such as artificial intelligence (AI) , cloud platforms, and wearable devices are enabling real-time monitoring and personalised treatment delivery across the region.

MEA Digital Therapeutics Market, By Application, 2025

• Diabetes - The segment dominated the market with a 28.00% share, due to rapid action, higher bioavailability and strong use in hospital-based treatments for severe conditions.
• Obesity - The segment accounted for 16.00% of the total market share, due to rising sedentary lifestyles, unhealthy diets, increasing demand for digital weight management and lifestyle intervention programs.
• Cardiovascular Diseases (CVD) - The segment accounted for 14.00% of the total market share, because of high prevalence of lifestyle- related risks, diabetes, and growing the option of digital monitoring and management solutions.

MEA Digital Therapeutics Market, By End-Use, 2025

• Patients - The segment dominated the market with a 34.00% share, due to rising self-care awareness, easier access to mobile health apps, and growing preference for home- based treatment solutions.
• Providers - The segment accounted for 26.00% of the total market share, because increasingly adopt digital tools to improve diagnosis, patient monitoring, treatment efficiency, and clinical decision-making outcomes.
• Payers - The segment accounted for 18.00% of the total market share, because insurers and government bodies increasingly support cost- effective digital treatments to reduce long-term health care expenses and improve outcomes.

Segments Covered in the Report

By Application

• Diabetes
• Obesity
• Cardiovascular Diseases (CVD)
• Respiratory Diseases
• Smoking Cessation
• CNS Diseases
• Others

By End-Use

• Patients
• Providers
• Payers
• Employers
• Others